Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
SOLO3: Olaparib outperforms chemo in heavily pretreated ovarian cancer
Key clinical point: For heavily pretreated patients with BRCA-mutated ovarian cancer, olaparib is more effective than nonplatinum chemotherapy.
Major finding: The objective response rate in the olaparib group was 72.2%, compared with 51.4% in the nonplatinum chemotherapy group (P = .002).
Study details: SOLO3 was a phase 3 trial of 266 patients with BRCA-mutated ovarian cancer who had received two or more previous lines of platinum-based chemotherapy.
Disclosures: SOLO3 was funded by AstraZeneca and Merck. The investigators reported additional relationships with Clovis Oncology, Eisai, Tesaro, and other companies.
Penson et al. J Clin Oncol. 2020 Feb 19. doi: 10.1200/JCO.19.02745.